Grace Therapeutics, Inc. (GRCE) Income Statement
GRCE FY2026 at a glance
Fiscal year ended March 31, 2026 · U.S. dollarsGRCE revenue and net income
GRCE profit margins
GRCE growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GRCE quarterly EPS vs estimates
Grace Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 12, 2026.
GRCE income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $309,318 | $0 | $0 | $0 | $0 |
| Cost of revenue | $6,999 | $7,000 | $11,000 | $124,000 | $0 | $119,938 | — | $3.1M | $2.7M | $2.6M |
| Gross profit | −$6,999 | −$7,000 | −$11,000 | −$124,000 | $0 | $189,378 | — | −$3.1M | −$2.7M | −$2.6M |
| Research & development | $2.4M | $13.5M | $6.4M | $13.5M | $6.9M | $6.6M | $31.9M | $29.4M | $12.1M | $7.2M |
| Sales, general & admin | $8.7M | $10.2M | $9.2M | $11.1M | $12.2M | $10.5M | $16.9M | $4.3M | $3.1M | — |
| Total operating expenses | $11.1M | $23.8M | $17.4M | $70.5M | $19.5M | $26.1M | $48.8M | $42.5M | $15.3M | $8.0M |
| Operating income | −$11.1M | −$23.8M | −$17.4M | −$70.5M | −$19.5M | −$25.9M | −$48.8M | −$34.4M | −$15.3M | −$10.5M |
| Interest income | $685,000 | $711,000 | $911,000 | $246,000 | $77,000 | $107,000 | — | — | — | — |
| Interest expense | — | — | — | — | — | $331,649 | $414,177 | $1.1M | $371,622 | $54,439 |
| Income before taxes | −$9.5M | −$18.2M | −$19.9M | −$70.3M | −$13.1M | −$31.1M | −$51.0M | −$39.4M | −$16.7M | −$10.7M |
| Income taxes | −$1.7M | −$4.6M | −$2.5M | −$12.9M | −$809,658 | — | — | — | — | −$121,083 |
| Net income | −$7.8M | −$13.6M | −$17.4M | −$57.4M | −$12.3M | −$31.1M | −$51.0M | −$39.4M | −$16.7M | −$10.6M |
| EBITDA | −$11.1M | −$23.7M | −$15.4M | −$24.6M | −$19.2M | −$15.5M | −$45.9M | −$36.8M | −$14.3M | −$8.0M |
| EPS (diluted) | −$0.64 | −$1.21 | −$1.43 | −$1.58 | −$1.11 | −$9.01 | −$31.94 | −$44.18 | −$76.82 | −$33.26 |
| Gross margin | — | — | — | — | — | 61.2% | — | — | — | — |
| Operating margin | — | — | — | — | — | −8,377.1% | — | — | — | — |
| Net margin | — | — | — | — | — | −10,039.8% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $8,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $2,000 | $4,116 | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 | $1,000 | $1,000 | $1,000 | $2,000 |
| Gross profit | — | −$2,000 | −$4,116 | −$2,000 | −$2,000 | −$2,000 | −$2,000 | −$2,000 | −$1,000 | −$1,000 | −$1,000 | −$2,000 |
| Research & development | $697,000 | $420,000 | $633,924 | $792,206 | $955,000 | $2.3M | $3.2M | $3.0M | $3.7M | $2.3M | $1.9M | $622,945 |
| Sales, general & admin | $1.7M | $308,589 | $2.7M | $2.7M | $2.1M | $2.2M | $2.2M | $1.9M | $3.1M | $2.1M | $2.1M | $2.3M |
| Total operating expenses | $15.8M | $3.0M | $3.4M | $3.5M | $3.1M | $4.5M | $5.3M | $4.8M | $6.8M | $4.4M | $4.0M | $2.8M |
| Operating income | −$15.8M | −$3.0M | −$3.4M | −$3.5M | −$3.1M | −$4.5M | −$5.3M | −$4.8M | −$6.8M | −$4.4M | −$4.0M | −$2.8M |
| Interest income | $141,000 | $138,000 | $170,000 | $172,000 | $205,000 | $167,000 | $138,000 | $172,000 | $235,000 | $249,000 | $316,000 | $212,000 |
| Income before taxes | −$15.8M | −$2.9M | −$3.2M | −$1.3M | −$3.4M | −$544,010 | −$6.8M | −$4.3M | −$4.6M | −$5.5M | −$3.4M | −$5.0M |
| Income taxes | — | −$1.7M | — | — | — | −$1.4M | −$870,044 | −$852,000 | −$990,164 | −$1.2M | −$275,702 | −$603,986 |
| Net income | −$15.8M | −$1.2M | −$3.2M | −$1.3M | −$3.4M | $905,733 | −$6.0M | −$3.4M | −$3.6M | −$4.3M | −$3.2M | −$4.4M |
| EBITDA | −$15.8M | −$3.0M | −$3.4M | −$3.5M | −$3.1M | −$4.5M | −$5.3M | −$4.8M | −$6.8M | −$4.4M | −$4.0M | −$2.8M |
| EPS (diluted) | −$0.91 | −$0.08 | −$0.19 | −$0.08 | −$0.29 | $0.05 | −$0.51 | −$0.42 | −$0.33 | −$0.36 | −$0.28 | −$0.31 |
| Gross margin | — | — | — | — | — | −25.0% | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | −56,661.8% | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | 11,321.7% | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GRCE's financial statements (latest annual report filed June 18, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GRCE financial results
Grace Therapeutics reported no revenue in fiscal year 2026 (ended March 31, 2026). It had a net loss of $7.8 million. Diluted earnings per share came to −$0.64.
See the GRCE stock overview for the latest quote and news, or the GRCE chart for price history and technical indicators.
GRCE income statement FAQ
Does Grace Therapeutics have revenue?
Grace Therapeutics reported no revenue for fiscal year 2026, which ended on March 31, 2026.
Is Grace Therapeutics profitable?
No. Grace Therapeutics reported a net loss of $7.8 million in fiscal 2026.
How much does Grace Therapeutics spend on research and development?
Grace Therapeutics spent $2.4 million on research and development in fiscal 2026.
What are Grace Therapeutics's earnings per share?
Grace Therapeutics earned $-0.64 per diluted share in fiscal 2026, compared with $-1.21 a year earlier.
When will Grace Therapeutics report its next earnings?
Grace Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Grace Therapeutics's fiscal year end?
Grace Therapeutics's fiscal year ends in March. The latest annual report covers the year ended March 31, 2026 and was filed on June 18, 2026.